UBS sees a rosy outlook ahead for CVS . The bank upgraded the pharmacy stock to a buy rating from neutral, with analyst Kevin Caliendo lifting his price target by 18%, to $79 from $67. Shares of CVS Health have already surged 53% this year, through Friday's close. Caliendo's updated target implies an additional 15% upside ahead for the stock. CVS YTD mountain CVS YTD chart "Despite the YTD improvement in shares, we continue to see incremental upside, both from a long-term EPS perspective, with multiple years of [double-digit] earnings growth ahead given multiple pathways (but primarily hinging on the [healthcare benefits] recovery), and from a valuation multiple perspective," the analyst wrote. "While it remains early in the tenure of the new management team, stability in messaging and con

See Full Page